Cellular sulfhydryls, especially glutathione (GSH), have been found to protect cells via detoxification of alkylating agents such as nitrogen mustard (Arrick & Nathan, 1984) . In fact, the relationship between the sensitivity of tumour cells to nitrogen mustard and their sulfhydryl contents has been demonstrated by several investigators (Hirono, 1961; Calcutt & Connors, 1963; Ball et al., 1966; Goldberg, 1969; Morita, 1973; Begleiter et al., 1983) . Additionally, the increased sensitivity of cells to melphalan following either the incubation of cells in cysteine-deficient medium or exposure to a non-protein sulfhydryl (NPSH) depleting agent, such as diethyl maleate (DEM) or buthionie sulfoximine (BSO), has been reported by several groups (Suzukake et al., 1982; Taylor et al., 1982; Green et al., 1984) .
Cyclophosphamide (CYC) is a widely used alkylating agent. According to the generally accepted mechanism for the generation of active metabolites, CYC becomes phosphoramide mustard, one of the nitrogen mustards, via oxidation to 4-hydroxycyclophosphamide in liver. Additionally, in other pathways for 4-hydroxycyclophosphamide, a formation of sulfhydryl reactive intermediates has been suggested (Ludlum, 1977; Cates & Li, 1982) . Therefore, the pretreatment of tumours with an NPSH depleting agent may potentiate the response of tumours to CYC. In fact, it has been reported that an increase in the response of murine tumours to CYC was obtained by a single treatment of BSO (Tomoshefsky et al., 1985) . The combination of BSO and CYC may have therapeutic benefit because the changes of GSH contents in Correspondence: K. Ono.
Received 1 April 1986; and in revised form, 30 June 1986. tissues following BSO treatments differ greatly from tissue to tissue (Griffith & Meister, 1979; Minchinton et al., 1984; Yu & Brown, 1984) and an optimal administration schedule of BSO may decrease the GSH content in tumours, but not in target organs of CYC.
One of the important roles of chemotherapy in cancer treatments is to eradicate micrometastases of tumours. In this study, we have examined the combined effect of multiple BSO pre-treatments and CYC on artificial lung micrometastases of murine tumours and bone marrow toxicity in mice.
Materials and methods
Mice and tumours Eight week old C3H/He male mice obtained from the animal centre of Kyoto University were used. They were caged in groups of 10 or less at a constant temperature with food and drinking water available ad libitum.
A fibrosarcoma, NFSa which arose spontaneously in a C3H mouse (Ando et al., 1979) , were provided by Dr. K. Ando (National Institute of Radiological Science, Chiba, Japan). The 17th generation of tumour was cryopreserved. When required, the contents of an ampoule were thawed and transplanted into a number of recipient mice. The outgrowing tumours were excised and minced. Tumour cell suspensions were then prepared enzymatically (0.2% trypsin, 0.02% pancreatin). lation. At this tumour volume, changes in NPSH content of tumours after BSO treatment were studied. For the study on the effect of cytotoxic treatments, artificial lung micrometastases were produced by injecting the viable tumour cells via the tail vein of the recipient mice. Ten days later, these micrometastases became macroscopic tumour nodules on the surface of the lung. In order to increase the formation rate of the tumour nodules in the lung, mice were treated with 150mg kg-1 CYC 24h previously and HIR (heavily irradiated, 100Gy) tumour cells were mixed with the viable cells (Ando et al., 1984) . A total of 2 x 106 tumour cells in 0.5ml were injected. The number of tumour nodules was directly proportional to the number of the viable tumour cells injected, and tumour nodules were enumerated up to 100 per lung. The formation rate of the tumour nodules in the lung of the control was -5%. Therefore, to construct the dose survival curve of the lung micrometastases, the mixture of HIR and the appropriate number of viable tumour cells which were expected to produce about 50 nodules after CYC treatment with or without BSO were injected via the tail vein. In 2 to 5 separate experiments, 10 to 25 mice in total were used for each point.
Drug treatment BSO was prepared as described by Griffith and Meister (1979) , and dissolved in sterile physiological saline (400mM). For measurement of NPSH contents in the tumours after BSO treatment, 5mmolkg-' BSO was injected s.c. into the posterior neck of mice 2 or 4 times every 12 h. Twelve hours after final injection of BSO, the tumours were excised and their NPSH contents were measured. For study of the combined effect of multiple BSO pretreatments and CYC toward lung micrometastases, 5 mmol kg-1 BSO was injected every 12 h in the manner described above. The BSO treatment was 48 h after i.v. injection of the tumour cells when BSO was administered twice every 12 h. When given four times, BSO was started 24 h after tumour cell injection. CYC was dissolved in physiological saline and was administered i.p. 12 h after the final BSO treatment, 72 h after tumour cell injection, in either BSO treatment schedule. To study bone marrow toxicity of the drugs, CYC was administered i.p. to non-tumour-bearing mice in combination with or without 4 injections of 5 mmol kg 1 BSO on the schedule described above.
Non-protein suithydryl (glutathione, cysteine) measurement This assay has been described in detail elsewhere (Komuro et al., 1985) . Briefly, 10% homogenates of tumours were prepared in 0.02 M ethylene diamine tetra acetic acid-disodium (EDTA) on ice. Aliquots (2.5 ml) of the homogenates were diluted with 2 ml H20 and 0.5 ml 50% trichloroacetic acid. The mixture was shaken vigorously and kept at 0°C for 15 min. The suspensions were centrifuged at 2000 g and 4°C for 10 min. Two ml of the supernatant were added to 4 ml of 0.4 M Tris buffer (pH 8.9), and 0.1 ml of 0.01 M DTNB was added and shaken. After filtering through a 0.22 gm millipore filter (Millipore, Bedford, MA, USA) absorbance at 412 nm of the sample solution was recorded on a spectrophotometer (UVIDEC 610 Spectrophotometer, Jasco, Tokyo, Japan) for the measurement of total non-protein sulfhydryl (NPSH). The sample was subjected to high-performance liquid chromatography (Hitachi Model 655 Solvent Delivery System, Tokyo, Japan) for measurement of GSH and cysteine content.
Measurement of lung micrometastases and bone marrow response Lungs were removed 10 days after treatment and fixed in Bouin's solution, and tumour nodules on the surface of the lungs were counted by eye. Surviving fractions of the lung micrometastases were obtained by dividing the formation rates of the tumour nodules at the CYC doses administered by that of the control.
Drug effects on normal bone marrow were determined by the spleen colony assay (Till & McCulloch, 1961) . Femurs from both legs of mice without tumours were removed 24 h after CYC treatment, and the marrow was washed out with 1 ml of cold physiological saline. Bone marrow suspensions from 3 mice were combined, nucleated cells counted and an adequate number of cells were then injected i.v. into 7 mice which had received wholebody gamma-irradiation (9 Gy) 24 h previously. Spleens were removed 8 days later, fixed in Bouin's solution and the numbers of colonies counted.
Results
Non-protein sulfJhydryl (glutathione, cysteine) depletion by BSO Figure 1 shows the changes of NPSH, GSH, and cysteine contents in NFSa tumours after repeated administration of 5 mmol kg-' of BSO. NPSH content in untreated tumours was 2.590mmolkg-1 which involves 2.067 mmolkg-' of GSH and 0.301 mmol kg-' of cysteine. Two BSO treatments given at 12h intervals reduced the NPSH, GSH and cysteine contents of tumours to 36.9, 24.0 and 84.7% of the untreated levels, respectively, 12 h after the second BSO treatment. Following four BSO treatments, the contents of NPSH, GSH and cysteine in tumours decreased to 14.1, 1.78, and 42.9% of the untreated levels, respectively, 12 h after the fourth BSO treatment.
Effects on lung micrometastases of NFSa tumour The response of lung micrometastases which were treated with CYC 12 h after tumour cell injection was described by an exponential survival curve with a small shoulder (Figure 2 ). When CYC treatment was 72 h after tumour cell injection, the dose survival curve was an exponential curve with an almost equal slope, but a large shoulder compared with the former (Figure 2 ). The cytotoxic effect of CYC on lung micrometastases was markedly enhanced when CYC was given to mice after two or four BSO treatments (Figure 3 ). Enhancement ratios (ERs) ranging from 2.41 (SF = 5%) to 2.73 (SF = 80%) were obtained when four BSO treatments were given before CYC administration. In the case of two BSO treatments, they ranged from 1.75 (SF=5%) to 1.83 (SF=40% (Figure 1) , and did not exhibit any untoward effects such as weight loss or death of a \ mice. Therefore, repeated administration of BSO -r' \alone on an optimal schedule appears to be a sufficient and safe method to deplete tumour GSH to very low levels. (multiplicity) in the 72 h-old vs. 12 h-old lung micrometastases.
In our experiments, the yield of tumour nodules affect the cytotoxicity of CYC on bone in the lung was not affected by BSO treatment. CFU-S. Rojas et al. (1984) reported that BSO treatment did not inhibit the growth of tumours. However, Midander and Revesz (1984) reported that BSO at in high doeses and long exposure time showed cytotoxicity and growth inhibitory effects toward V79 nges in GSH contents in tumours of mice cells. Pronounced cytotoxic effects of prolonged O treatment have been examined by several exposure to high doses of BSO were observed in tors. Minchinton et al. (1984) reported other cell lines (Shrieve & Harris, 1986) . In in vitro n GSH depletion down to 38% in the systems, BSO at low doses and short exposure time tumour and 57% in SAFA tumour, has not exhibited cytotoxicity . ely, 8 or 12 h after treatment with It has been reported that BSO administered to mice g-I of D, L,-BSO. Rojas et al. (1984) is completely excreted or metabolized within 24 h he same lines of tumours repeatedly with a (Griffith, 1982) . Therefore, the discrepancy between se of 0.5 or 1.0mmolkg-1, but maximum the results may be caused by the different BSO pletion was to 37.8% of the control values. exposure times.
Brown (1984) have reported that GSH BSO increased the sensitivity of the lung microin EMT6 and KHT tumours treated with metastases of NFSa tumour cells to CYC (Figure 3 ). doses, higher than 0.33mmolkg-1, Further, this increase appears to correlate inversely d to minimum levels 6 to 8 h after the with the GSH level at the time of CYC treatment, it, and complete recovery in GSH contents because four BSO treatments decreased GSH ieved by 24h. They also reported that the content of NFSa tumours to a lower level ntents in five different tumour lines treated compared with two BSO treatments. Tomashefsky ily doses of 1 or 3 mmol kg-I of BSO et al. (1985) have reported a similar phenomenon, d, respectively, to 20-50%, and 19-40% of showing that the growth delay time of MBT-2 rol values. In order to get further GSH tumour, a transplantable murine bladder tumour, i they combined DEM (300mgkg-1) with after CYC treatment correlated inversely with GSH iulting in a decrease to 8% of the control contents. Somfai-Relle et al. (1984) have also our studies, 5 mmol kg-I of D, L,-BSO was reported that the sensitivity of L1210 leukaemia cells to L-PAM becomes higher with longer BSO treatments (i.e., at lower GSH levels). In our studies, the ERs of BSO treatments were large at high survival levels (i.e., at small CYC doses). This finding may be applicable to cancer therapy, because small doses of CYC are administered repeatedly in clinical cancer chemotherapy.
The sensitivity of bone marrow cells to CYC did not increase after BSO treatment (Figure 4) . Moreover, BSO did not affect the yield of nucleated cells per femur (data not presented). It is not possible by available methods to measure the GSH content of bone marrow stem cells. However, GSH content in whole bone marrow cells decreased to minimum levels and completely recovered, 4 and 12h respectively after the treatment with 5 mmol kg-1 of D, L,-BSO (Komuro et al., unpublished) . Therefore, it seems probable that the treatment with BSO at an interval of 12 h did not decrease the GSH content in bone marrow stem cells to levels low enough to increase the sensitivity to CYC.
In conclusion, our results suggest that multiple BSO treatment on an appropriate administration schedule can increase the sensitivity of tumours to CYC without changing that of bone marrow stem cells. However, more toxicity studies on other critical normal tissues (e.g. gut) are needed before clinical application can be considered.
